Literature DB >> 12798834

The diagnosis of heart failure in general practice: implications for the UK National Service Framework.

Nigel Sparrow1, David Adlam, Alan Cowley, John R Hampton.   

Abstract

BACKGROUND: The UK National Service Framework recommends patients with suspected heart failure undergo echocardiography. Selection of patients for this investigation in primary care is difficult. It is not clear which clinical features best identify patients with left ventricular systolic dysfunction. AIM: Using echocardiography, to establish the accuracy of primary care diagnosis of left ventricular systolic dysfunction. To investigate the sensitivity, specificity and predictive values of clinical features in the diagnosis of left ventricular systolic dysfunction. STUDY: A cross-sectional study of 621 patients from a population prescribed loop diuretics in 7 general practices.
METHOD: Clinical diagnoses were extracted from general practice records. Symptoms, clinical signs, ECG features, brain natriuretic peptide levels and echocardiographic findings were studied in a research clinic.
RESULTS: Left ventricular systolic dysfunction (ejection fraction <40%) was present in 50% of 621 patients prescribed loop diuretics in primary care. General practice diagnoses showed high false positive rates. Individual or combinations of clinical features did not accurately predict left ventricular systolic dysfunction.
CONCLUSION: These results suggest the clinical diagnosis of left ventricular systolic dysfunction is inaccurate in this population. General practitioners should have a low threshold for referring patients prescribed loop diuretics for echocardiography. Increased open access echocardiography facilities will be needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798834     DOI: 10.1016/s1388-9842(03)00046-1

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

1.  Spironolactone and risk of upper gastrointestinal events: association is unproved.

Authors:  Muhammad F Dawwas
Journal:  BMJ       Date:  2006-09-02

2.  Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.

Authors:  Wan A H Wan Md Adnan; Nur L Zaharan; Kathleen Bennett; Catherine A Wall
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 3.  Diagnosis of heart failure in primary care.

Authors:  Cândida Fonseca
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

4.  Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study.

Authors:  Willeke N Kasje; Petra Denig; Roy E Stewart; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Eur J Clin Pharmacol       Date:  2005-03-11       Impact factor: 2.953

Review 5.  Management of chronic heart failure: perceived needs of general practitioners in light of the new general medical services contract.

Authors:  S J Leslie; S P McKee; E A Imray; M A Denvir
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

6.  Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP.

Authors:  G Mak; M Ryder; N F Murphy; C O'Loughlin; D McCaffrey; M Ledwidge; K McDonald
Journal:  Ir J Med Sci       Date:  2008-07-17       Impact factor: 1.568

7.  Evaluation of B-type natriuretic peptide for validation of a heart failure register in primary care.

Authors:  Gurbir S Bhatia; Michael D Sosin; Jane Stubley; Jeetesh V Patel; Elizabeth A Hughes; Rebecca Gibbs; Russell C Davis
Journal:  BMC Cardiovasc Disord       Date:  2007-07-30       Impact factor: 2.298

Review 8.  The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review.

Authors:  V Madhok; G Falk; A Rogers; A D Struthers; F M Sullivan; T Fahey
Journal:  BMC Fam Pract       Date:  2008-10-08       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.